Pictet Asset Management Holding SA Purchases 11,691 Shares of Krystal Biotech, Inc. $KRYS

Pictet Asset Management Holding SA increased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 10.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 119,489 shares of the company’s stock after acquiring an additional 11,691 shares during the period. Pictet Asset Management Holding SA’s holdings in Krystal Biotech were worth $39,737,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. AlphaCentric Advisors LLC lifted its holdings in shares of Krystal Biotech by 5.2% during the third quarter. AlphaCentric Advisors LLC now owns 2,046 shares of the company’s stock valued at $680,000 after acquiring an additional 101 shares during the period. Parallel Advisors LLC boosted its stake in shares of Krystal Biotech by 2.0% in the 3rd quarter. Parallel Advisors LLC now owns 1,733 shares of the company’s stock valued at $576,000 after purchasing an additional 34 shares in the last quarter. Heritage Family Offices LLP acquired a new stake in shares of Krystal Biotech in the 3rd quarter valued at $25,000. Provenance Wealth Advisors LLC bought a new stake in shares of Krystal Biotech in the 3rd quarter worth about $201,000. Finally, Bridge City Capital LLC grew its holdings in shares of Krystal Biotech by 21.9% in the 3rd quarter. Bridge City Capital LLC now owns 14,404 shares of the company’s stock worth $4,790,000 after purchasing an additional 2,588 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. This trade represents a 1.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

KRYS has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $361.00 price target on shares of Krystal Biotech in a report on Thursday, October 15th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. Royal Bank Of Canada reduced their target price on Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating on the stock in a report on Tuesday, November 3rd. Finally, TD Cowen decreased their price target on Krystal Biotech from $403.00 to $380.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $375.00.

Krystal Biotech Trading Up 1.1%

KRYS opened at $306.50 on Wednesday. The stock has a market capitalization of $9.08 billion, a PE ratio of 41.59 and a beta of 0.56. Krystal Biotech, Inc. has a 1-year low of $198.02 and a 1-year high of $382.54. The firm has a 50-day moving average price of $330.45 and a two-hundred day moving average price of $309.29.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 2nd. The company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.79 by $0.26. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. The business had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. On average, research analysts predict that Krystal Biotech, Inc. will post 7.74 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.